Tag

ODAC Archives - JDDonline - Journal of Drugs in Dermatology

Starting Your Own Dermatology Practice: Expert Panel Discussion

By JDD Webinars No Comments

JDD Multimedia

Video Pearls

In this exclusive Webcast, expert panelists discuss their experiences with securing financing, choosing devices, hiring contractors and running a practice. They also provide insights into what they wish they knew before beginning their practice, offer practical tips and much more!

 

Supported by

Starting Your Own Dermatology Practice

Expert Panel Discussion

ODAC in partnership with the JDD, invite you to join your dermatology colleagues as we discuss strategies, steps and best practices for starting your own dermatology practice.
In this exclusive Webcast, expert panelists discuss their experiences with securing financing, choosing devices, hiring contractors and running a practice. They also provide insights into what they wish they knew before beginning their practice, offer practical tips and much more!

 

View on Demand Now

MODERATOR

  • Aanand N. Geria, MD, FAAD (Founder, Geria Dermatology – Rutherford, NJ)

PANELISTS

  • Matthew J. Elias, DO, FAAD (Co-Founder, Elias Dermatology – Fort Lauderdale, FL)
  • Rishi K. Gandhi, MD, FAAD (CEO & Director, Ohio Skin Surgery and Cosmetic Center – Dayton, OH)
  • Chesahna Kindred, MD, MBA, FAAD (Founder, Kindred Hair & Skin Center – Columbia, MD)
  • Omar N. Qutub, MD FAAD (Founder, Dermatology By Design LLC – Portland, OR)

View more on-demand webcasts from the JDD.

JDD Webinars

You May Also Like

Oral Collagen Supplementation: A Systematic Review of Dermatological Applications

| Aesthetics, Featured Articles | No Comments
800 patients who took up to 10 grams of collagen per day, experienced improvement in skin elasticity, moisture retention, and increased density of collagen fibers in the skin. Improvements in…

NEW from the JDD Podcast: “The Science of Sun Protection”

| Photoprotection, Podcast Highlights, Skin Cancer | No Comments
iTunes Google Play Stitcher TuneIn Dr. Neal Bhatia and Dr. Adam Friedman   Photoprotection works, plain and simple. Yet all too often we must defend good science, dispel unfounded myths,…

The Science of Sun Protection

| Podcast | No Comments
Episode 1 of a 2-Part Series: "Sun Protection: A Review of Current Interventions and Barriers to Changing Patient Attitude and Behavior" Photoprotection works, plain and simple. Yet all too often…

Controversies in Photoprotection

By Derm Community, ODAC, Photoprotection, Skin Cancer No Comments

Dermatology News

Video Pearls

Adam Friedman, MD, FAAD is Professor and Interim Chair of Dermatology and serves as Residency Program Director, Director of Translational Research, and Director of the Supportive OncodermatologyProgram in the Department of Dermatology at The George Washington University School of Medicine & Health Sciences. Dr. Friedman completed his undergraduate training at the University of Pennsylvania and graduated with Distinction in Dermatologic Research at the Albert Einstein College of Medicine in New York.

Learn More

Controversies in Photoprotection

featuring Dr. Adam Friedman

Journal of Drugs in Dermatology partners Next Steps in Derm and ODAC Dermatology Aesthetic and Surgical Conference interviewed Dr. Adam Friedman, Professor, Interim Chair of Dermatology, and Residency Program Director at George Washington University, on some of the common misconceptions and controversies surrounding photoprotection.

Debunking Misconceptions on Photoprotection

While ample evidence has shown that sunscreen not only reduces the incidences of melanoma, it also helps prevent  accelerated skin aging, many misconceptions about sunscreen are preventing patients from using what we have available to them.

Watch as Dr. Friedman debunks some of the current myths surrounding photoprotection and provides guidance on what we should really pay attention to.

Explore Photoprotection Articles

ODAC Orlando Dermatology, Aesthetic & Surgical Conference

ODAC Dermatology, Aesthetic and Surgical Conference (ODAC) is a distinguished ACCME accredited dermatology conference designed to meet the needs of medical and aesthetic dermatology providers in the 21st century. Founded in 2003 by dermatology pioneer, Dr. Perry Robins, the ODAC Dermatology Conference provides nearly 700 dermatologists, residents, nurse practitioners and physician assistants with important annual updates and fresh practical pearls in the field of medical, cosmetic and surgical dermatology in a highly interactive format.

Reasons to Attend ODAC 2021

  • Discuss the next generation of diagnostic approaches and evidence-based dermatology treatments
  • Observe cutting-edge procedures and techniques with live demonstrations of novel products and emerging technologies
  • Review clinical trial results and discuss case-studies in both large and small group settings
  • Cultivate relationships with colleagues and leaders actively shaping the future of dermatology
  • Earn CME –  up to 31 AMA PRA Category 1 Credits™
Register for ODAC 2021 Now

You May Also Like

Oral Collagen Supplementation: A Systematic Review of Dermatological Applications

| Aesthetics, Featured Articles | No Comments
800 patients who took up to 10 grams of collagen per day, experienced improvement in skin elasticity, moisture retention, and increased density of collagen fibers in the skin. Improvements in…

NEW from the JDD Podcast: “The Science of Sun Protection”

| Photoprotection, Podcast Highlights, Skin Cancer | No Comments
iTunes Google Play Stitcher TuneIn Dr. Neal Bhatia and Dr. Adam Friedman   Photoprotection works, plain and simple. Yet all too often we must defend good science, dispel unfounded myths,…

The Science of Sun Protection

| Podcast | No Comments
Episode 1 of a 2-Part Series: "Sun Protection: A Review of Current Interventions and Barriers to Changing Patient Attitude and Behavior" Photoprotection works, plain and simple. Yet all too often…

Does This Skin Cancer Really Need Mohs?

By Derm Community, ODAC, Skin Cancer No Comments

Dermatology News

National Skin Cancer Month

The discussion was led by Dr. Vishal Patel and Dr. Sailesh Konda, and was moderated by Dr. William Hanke.

Learn More

Does This Skin Cancer Really Need Mohs? Highlights from the 17th Annual ODAC Conference

In recognition of National Skin Cancer Month, the Journal of Drugs in Dermatology and our industry partners, Next Steps, are taking a look back at an engaging panel discussion, “Does This Skin Cancer Really Need Mohs?,” from the 17th Annual ODAC Dermatology, Aesthetic and Surgical Conference in Orlando, Florida.

The case-based discussion examined the use of Mohs micrographic surgery (MMS) versus other treatment modalities for non-melanoma skin cancers, Merkel cell carcinoma, and lentigo maligna.

Case I: Highlights

The first case described a 41-year-old Fitzpatrick type II female with two superficial basal cells on her right central cheek (5×7 mm) and right chin (6×8 mm). Mohs Appropriate Use Criteria (AUC) score is 7 for both lesions, justifying MMS for both lesions. Pretty straightforward right?

Think again. Dr. Patel implored the use of topical immunotherapy with imiquimod for these lesions given a study by Williams et al. (1). This randomized clinical trial examined the interventions of either imiquimod 5% cream once daily (superficial basal cell carcinoma, 6 weeks; nodular basal cell carcinoma, 12 weeks) or excisional surgery (4-mm margin) on 3- and 5-year success rates. The 3-year success rate was defined as the clinical absence of initial failure or signs of recurrence at the 3-year dermatology review, and Five-year success was defined as 3-year success plus absence of recurrences identified through medical records. The 5-year success rates for imiquimod were 82.5% compared with 97.7% for surgery (relative risk of imiquimod success = 0.84, 95% confidence interval = 0.77-0.91, P < 0.001). These were comparable to year 3 success rates. Most imiquimod treatment failures occurred in year 1.

View More on Next Steps

This information was presented by Dr. Vishal Patel and Dr. Sailesh Konda at the 17th ODAC Dermatology, Aesthetic and Surgical Conference held January 17th-20st, 2020 in Orlando, FL.

Further case highlights can be reviewed by visiting Next Steps in Derm.

More on Mohs

ODAC Orlando Dermatology, Aesthetic & Surgical Conference

ODAC Dermatology, Aesthetic and Surgical Conference (ODAC) is a distinguished ACCME accredited dermatology conference designed to meet the needs of medical and aesthetic dermatology providers in the 21st century. Founded in 2003 by dermatology pioneer, Dr. Perry Robins, the ODAC Dermatology Conference provides nearly 700 dermatologists, residents, nurse practitioners and physician assistants with important annual updates and fresh practical pearls in the field of medical, cosmetic and surgical dermatology in a highly interactive format.

Reasons to Attend ODAC 2021

  • Discuss the next generation of diagnostic approaches and evidence-based dermatology treatments
  • Observe cutting-edge procedures and techniques with live demonstrations of novel products and emerging technologies
  • Review clinical trial results and discuss case-studies in both large and small group settings
  • Cultivate relationships with colleagues and leaders actively shaping the future of dermatology
  • Earn CME –  up to 31 AMA PRA Category 1 Credits™
Register for ODAC 2021 Now

You May Also Like

Oral Collagen Supplementation: A Systematic Review of Dermatological Applications

| Aesthetics, Featured Articles | No Comments
800 patients who took up to 10 grams of collagen per day, experienced improvement in skin elasticity, moisture retention, and increased density of collagen fibers in the skin. Improvements in…

NEW from the JDD Podcast: “The Science of Sun Protection”

| Photoprotection, Podcast Highlights, Skin Cancer | No Comments
iTunes Google Play Stitcher TuneIn Dr. Neal Bhatia and Dr. Adam Friedman   Photoprotection works, plain and simple. Yet all too often we must defend good science, dispel unfounded myths,…

The Science of Sun Protection

| Podcast | No Comments
Episode 1 of a 2-Part Series: "Sun Protection: A Review of Current Interventions and Barriers to Changing Patient Attitude and Behavior" Photoprotection works, plain and simple. Yet all too often…

Melasma: Treatment Pearls from the Expert

By Derm Community, ODAC No Comments

Dermatology News

Video Pearls

E. Victor Ross, MD, is a dermatologist specializing in laser surgery of the skin. He uses a broad array of technologies to reduce red and brown skin lesions, wrinkles and unwanted hair, improve spider veins of the legs and improve the appearance of scars, including acne scars.

Learn More

Melasma: Treatment Pearls from the Expert

featuring Dr. Vic Ross

Journal of Drugs in Dermatology partners Next Steps in Derm and ODAC Dermatology Aesthetic and Surgical Conference interviewed Dr. Vic Ross, Director of the Scripps Clinic Laser and Cosmetic Dermatology Center in San Diego on his approach and the various interventions he uses for the treatment of Melasma.

More On Melasma

Melasma is a commonly condition that mostly affects women with Fitzpatrick skin types III-VI with prominent brown pigmentation with or without an underlying erythema. Treating Melasma is challenging, due to its chronic nature.

Explore Melasma Articles

ODAC Orlando Dermatology, Aesthetic & Surgical Conference

ODAC Dermatology, Aesthetic and Surgical Conference (ODAC) is a distinguished ACCME accredited dermatology conference designed to meet the needs of medical and aesthetic dermatology providers in the 21st century. Founded in 2003 by dermatology pioneer, Dr. Perry Robins, the ODAC Dermatology Conference provides nearly 700 dermatologists, residents, nurse practitioners and physician assistants with important annual updates and fresh practical pearls in the field of medical, cosmetic and surgical dermatology in a highly interactive format.

Reasons to Attend ODAC 2021

  • Discuss the next generation of diagnostic approaches and evidence-based dermatology treatments
  • Observe cutting-edge procedures and techniques with live demonstrations of novel products and emerging technologies
  • Review clinical trial results and discuss case-studies in both large and small group settings
  • Cultivate relationships with colleagues and leaders actively shaping the future of dermatology
  • Earn CME –  up to 31 AMA PRA Category 1 Credits™
Register for ODAC 2021 Now

You May Also Like

Oral Collagen Supplementation: A Systematic Review of Dermatological Applications

| Aesthetics, Featured Articles | No Comments
800 patients who took up to 10 grams of collagen per day, experienced improvement in skin elasticity, moisture retention, and increased density of collagen fibers in the skin. Improvements in…

NEW from the JDD Podcast: “The Science of Sun Protection”

| Photoprotection, Podcast Highlights, Skin Cancer | No Comments
iTunes Google Play Stitcher TuneIn Dr. Neal Bhatia and Dr. Adam Friedman   Photoprotection works, plain and simple. Yet all too often we must defend good science, dispel unfounded myths,…

The Science of Sun Protection

| Podcast | No Comments
Episode 1 of a 2-Part Series: "Sun Protection: A Review of Current Interventions and Barriers to Changing Patient Attitude and Behavior" Photoprotection works, plain and simple. Yet all too often…

Long Term Use of Novel Therapeutic for Topical Treatment of Primary Axillary Hyperhidrosis in Pediatric Subjects

By Derm Community No Comments

Source: ODAC Dermatology, Aesthetic & Surgical Conference (ODAC) Discovery in Dermatology Poster Session

At the 17th Annual ODAC Dermatology, Aesthetic, and Surgical Conference (ODAC) held January 17-20 in Orlando, FL, Brandon Kirsch, MD, Janet DuBois, MD, Martin N. Zaiac, MD and Deepak Chadha, MS, MBA, RAC presented scientific research of long term data with a novel therapeutic for topical treatment of primary axillary hyperhidrosis in pediatric subjects.

Discovery in Dermatology

The use of retro-metabolically designed drugs in dermatology is novel and has the potential for providing significant therapeutic benefit to pediatric and adult patients.

Sofpironium bromide is an ester analogue of glycopyrrolate that inhibits muscarinic receptors in sweat glands. It was developed according to the principles of retro-metabolic drug design, in which the goal is to create an active compound that is metabolized in vivo to an inactive moiety in a single, predictable reaction. Retro-metabolically designed drugs are rapidly metabolized in the bloodstream, potentially allowing for optimal therapeutic effect at application sites with minimal systemic side effects.

Introduction

~2.1% of the US population aged <18 years has primary hyperhidrosis (HH); ~65% have axillary HH. Long-term safety/tolerability and efficacy of topical HH treatments have rarely been studied in pediatric patients. Sofpironium bromide is a retro-metabolically designed analog of glycopyrrolate (anticholinergic) in development for topical treatment of primary axillary HH. Absorbed drug is rapidly metabolized, potentially allowing optimal local therapeutic effect with minimal systemic effects..

Procedures

21 of 25 subjects (age 9-16 yrs) with primary axillary HH of ≥6 months duration, completing a previous 1-week safety and pharmacokinetic (PK) study (BBI-4000-CL-105), were enrolled. Objectives were to assess safety/tolerability and PK, and explore efficacy of sofpironium bromide gel, 15% applied to both axillae for 24 weeks.

Results

Mean age (SD) 13.3 (2.29) years. 16 subjects completed this 24-week study. 7 had treatment emergent adverse events (TEAEs); 4 with AEs related to study drug, including expected systemic anticholinergic AEs (blurred vision, dry mouth, dry eyes, mydriasis) and local events (pain, pruritus, rash, erythema). 2 subjects discontinued due to TEAEs, including dry eye, dry mouth, local pruritus, local rash. The majority (52.4%) of subjects did not have any local symptoms/signs, and none observed were severe in nature. PK did not show evidence of drug/major metabolite accumulation, with most subjects having concentrations not quantifiable. The validated patient-reported outcome, Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax), showed mean (SD) change from baseline (from previous study) to Week 24 of this study of -1.91 (1.038). A -1.00 change shows clinically meaningful improvement.

Conclusion

In this 24-week study in pediatric subjects sofpironium bromide, 15% was safe/well tolerated. Majority of subjects had no TEAE, and there were no severe or serious AEs. There was no evidence of drug accumulation. There was indication of clinically meaningful improvement in axillary HH.

Be an expert among experts, join the JDD at ODAC to hear from the esteemed faculty members featured in top media outlets.

Learn more

You May Also Like

Derm Community
June 16, 2020

A Must-Read: The Business of Dermatology

Edited by Drs. Jeffrey S. Dover and Kavita Mariwalla, and authored by impressive experts in the field, The Business of Dermatology offers a comprehensive guide to opening, maintaining, and sustaining…
Derm CommunityODACPhotoprotectionSkin Cancer
June 1, 2020

Controversies in Photoprotection

Adam Friedman, MD, FAAD is Professor and Interim Chair of Dermatology and serves as Residency Program Director, Director of Translational Research, and Director of the Supportive OncodermatologyProgram in the Department…
Derm CommunityODACSkin Cancer
May 18, 2020

Does This Skin Cancer Really Need Mohs?

The discussion was led by Dr. Vishal Patel and Dr. Sailesh Konda, and was moderated by Dr. William Hanke. In recognition of National Skin Cancer Month, the Journal of Drugs…

Dr. Susan Weinkle Recognized as Outstanding Educator & Mentor in Dermatology at ODAC 2020

By Derm Community No Comments

Dr. Susan H. Weinkle was awarded the Outstanding Educator & Mentor in Dermatology Award by the ODAC Dermatology, Aesthetic & Surgical Conference  for her commitment to educating and mentoring the next generation of dermatologists.

“Physicians around the globe have learned so much from Dr. Susan Weinkle. [Dr. Weinkle] has given all of us in aesthetics so much of her time and energy, and I am honored to present this award to her,” says Joel Cohen, M.D., and ODAC vice conference chair.

Dr. Weinkle currently serves as assistant clinical professor of dermatology at the University of South Florida, Tampa, Fla, and is in private practices in Bradenton, Fla., where she specializes in Mohs Micrographic Surgery and cosmetic dermatology.

A past president of the Women’s Dermatological Society and the American Society for Dermatologic Surgery, Dr. Weinkle is also the former  committee chair and member of the board of directors of several dermatology organizations, including the American Academy of Dermatology, Dermatology Foundation, and Florida Society of Dermatology and Dermatologic Surgery.

Award recipients are nominated and chosen by a committee of thought leaders in dermatology, as well as dermatology practitioners. The award is presented at ODAC in partnership with the Journal of Drugs in Dermatology (JDD).

Learn More

You May Also Like

Derm Community
June 16, 2020

A Must-Read: The Business of Dermatology

Edited by Drs. Jeffrey S. Dover and Kavita Mariwalla, and authored by impressive experts in the field, The Business of Dermatology offers a comprehensive guide to opening, maintaining, and sustaining…
Derm CommunityODACPhotoprotectionSkin Cancer
June 1, 2020

Controversies in Photoprotection

Adam Friedman, MD, FAAD is Professor and Interim Chair of Dermatology and serves as Residency Program Director, Director of Translational Research, and Director of the Supportive OncodermatologyProgram in the Department…
Derm CommunityODACSkin Cancer
May 18, 2020

Does This Skin Cancer Really Need Mohs?

The discussion was led by Dr. Vishal Patel and Dr. Sailesh Konda, and was moderated by Dr. William Hanke. In recognition of National Skin Cancer Month, the Journal of Drugs…

The Top Ten Reasons to Attend ODAC 2020 & Beyond!

By Derm Community
ODAC 2020
Connect with your colleagues at ODAC 2020

ODAC 2020 is in full swing in Orlando, Florida.

ODAC Dermatology, Aesthetic and Surgical Conference (ODAC) is a ACCME accredited dermatology conference designed to meet the needs of medical and aesthetic dermatology providers in the 21st century.

Dermatologists from around the world attend ODAC to stay informed and up-to-date on clinical dermatology updates, new treatments, new uses for old treatments, new product lines, changes to therapeutic guidelines and to witness live demonstrations from the experts.

If you have been considering attending ODAC but have not yet attended the conference, here is a list of the Top Ten Reasons You Should be Attending ODAC in 2020 and Beyond!

Reason #1: Gain Fresh Practical Pearls & Real Advice

  • Gain insights from the experts on how they personally apply updates to their practice.

Reason #2: ODAC is the Perfect Blend of Medical, Aesthetic, and Surgical Dermatology

  • ODAC is the comprehensive, interactive and unique yearly dermatology conference that offers top content in a diverse, “one-stop-shop” format.

Reason #3:  Enjoy 10+ Hours of Live Demonstrations and Advanced Technique Instructions

  • Observe cutting-edge procedures and techniques with live demonstrations of new products and emerging technologies.

Reason #4:  Comprehensive Updates, Expertly Curate

  • Stay informed and updated with critical updates curated by practicing medical, surgical and aesthetic dermatology trailblazers.

Reason #5:  New Uses, Old Treatments

  • Evaluate new uses for old treatments and assess off-label uses for common dermatology conditions.

Reason #6:  Expanded Programming and Session Options

  • We’ve expanded the 2020 program to include additional expert sessions to accommodate the needs to today’s dermatology provider.

Reason #7:  Connect with Your Dermatology Community

  • Cultivate relationships with colleagues and leaders actively shaping the future of dermatology!

Reason #8:  View Clinical Trial Results

  • Review clinical trial results and discuss case-studies in both large and small group settings

Reason #9:  Discover New Diagnostic Approaches

  • Discuss the next generation of diagnostic approaches and evidence-based dermatology treatments

Reason #10:  Earn 31 AMA PRA CATEGORY 1 CREDIT(S)™

See you at ODAC!

For more information on ODAC Registration, visit www.orlandoderm.org.

Learn More